review glp-1 receptor agonists show promise in treating substance use disorders Current Insights, Advantages and Challenges

In addiction research, we could use behavioral neuroscience approaches to understand clear connections between behavioral outcomes and drug treatments

Renal function must be considered, as some GLP-1 agents require dose adjustment or have limitations in advanced chronic kidney disease

Pair this with oscillating fans placed low to the ground to help evaporate moisture before it settles into a dangerous puddle

Asian and South Asian populations in particular show cardiometabolic risk at lower BMI thresholds some guidelines use BMI 25+ as obesity for these populations

The treatments today are as ineffective as they will ever be, looking ahead: Weight loss efficacy is increasing from 15% to 20% to 25% to 30% The label is expanding from Diabetes to Obesity to Heart Disease and likely Kidney Disease and Sleep Apnea

They did it all wrong, Fusco said